Purple Biotech Ltd.

Regulatory Filings • Jul 8, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K KITOV PHARMA LTD.Press Release:Kitov Pharma Receives Notice false

����� ����� ��"�	2 380
KITOV PHARMA LTD
Corporation no: 520031238	12724
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	08/07/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-065494	Time of broadcast: 15:04 15:01:32

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K KITOV PHARMA LTD. Press Release:Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody

ea123933-6k_kitovpharmaEDGAR1i_Bannerless_isa.pdf

����� ����� ����� �� ����� ������ ���� �CM-24
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 23/06/2020
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101   , Israel Tel: 03-9333121 , Fax: 03-5097196
E-mail address: info@kitovpharma.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel